Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.63 |
| ▸ | IGF1R | P08069 | 2/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.58 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24900465 | 0.91 | EGFR (0.68) | EGFRKCNH2IGF1RERBB2ERBB3 | |
| SCHEMBL30221613 | 0.90 | EGFR (0.65) | EGFRKCNH2IGF1R | |
| SCHEMBL30221338 | 0.90 | EGFR (0.60) | EGFRKCNH2IGF1RERBB2ERBB3 | |
| SCHEMBL24900840 | 0.90 | EGFR (0.65) | EGFRKCNH2IGF1R | |
| SCHEMBL24900772 | 0.90 | EGFR (0.60) | EGFRKCNH2IGF1RERBB2ERBB3 | |
| SCHEMBL24900771 | 0.88 | EGFR (0.50) | EGFRKCNH2IGF1RERBB2ERBB3 | |
| SCHEMBL30221274 | 0.88 | EGFR (0.58) | EGFRKCNH2IGF1R | |
| SCHEMBL24900573 | 0.88 | EGFR (0.58) | EGFRKCNH2IGF1R | |
| SCHEMBL24900564 | 0.87 | EGFR (0.55) | EGFRKCNH2IGF1R | |
| SCHEMBL24900606 | 0.87 | EGFR (0.63) | EGFRKCNH2IGF1RERBB2ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023287783-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287783-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |